Hutch News

Hutch News

Stories tagged 'ASH 2016'

'Can't sit and wait': Gene therapy trial aims to cure rare Fanconi anemia

At annual hematology meeting, Fred Hutch researchers updated their treatment of 11-year-old Behzad

Dec. 4, 2016 | By Bill Briggs / Fred Hutch News Service

Behzad, 11, and his mom traveled from Mumbai, India to Seattle so he could be the first child to enroll in a Phase 1 Fred Hutch gene therapy study to try to correct his Fanconi anemia.

View story >


Dr. Marie Bleakley

12 questions about life outside the lab for the Fred Hutch pediatric immunotherapy and transplantation researcher

Nov. 21, 2016 | By Susan Keown

Get to know Dr. Marie Bleakley, Fred Hutch researcher, mother and proponent of clones.

View story >


Replenishing immune cells after remission

New approach, not yet tested in humans, aims to restore immune-powering B cells in cancer patients following successful CAR T-cell therapy

Oct. 17, 2016 | By Bill Briggs / Fred Hutch News Service

Scientists at Fred Hutch, Seattle Children’s Research Institute, and Technical University of Munich showed that activating a “kill switch” can turn off CAR T cells after doctors deem a cancer defeated, allowing normal B cells to again flourish.

View story >


For high-risk leukemia patients, umbilical cord blood transplant associated with lower risk of relapse

Study compares ‘alternative’ donor source vs. traditional transplantation of blood stem cells from an adult, unrelated donor

Sept. 7, 2016 | By Rachel Tompa / Fred Hutch News Service

A new study by Fred Hutch researchers, published today in The New England Journal of Medicine, has found that umbilical cord blood transplants may have advantages beyond being an alternative source of stem cells for patients without a traditional donor match. They also are associated with a lower risk of relapse in high-risk leukemia patients.

View story >


Patients with advanced lymphoma in remission after T-cell therapy

New study: 7 of 11 trial participants who got two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission

Sept. 7, 2016 | By Susan Keown / Fred Hutch News Service

Seven of 11 trial participants who got a two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission, a new study found.

View story >


Dr. Aude Chapuis

10 questions about life outside the lab for the Fred Hutch immunotherapy researcher

June 15, 2016 | By Bill Briggs / Fred Hutch News Service

Immunotherapy researcher Dr. Aude Chapuis moved from Switzerland to the United States in 2003. Get to know the avid skier and parent to a Play-Doh chef.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.